Medical University of South Carolina - Cancer Center Support Grant
南卡罗来纳医科大学 - 癌症中心支持补助金
基本信息
- 批准号:8322869
- 负责人:
- 金额:$ 5.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-01 至 2014-03-31
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAddressBiometryCancer BiologyCancer BurdenCancer CenterCancer Center Support GrantCancer ControlCancer Immunology ScienceCancer Research ProjectCell SeparationChargeClinicalClinical TrialsCommitDentalDevelopmentDiagnosisDiscipline of NursingExtramural ActivitiesFlow CytometryFundingFutureGrantGrowthHealth OccupationsInvestmentsLipidsMalignant NeoplasmsMedicalMedicineMissionMolecularMorbidity - disease rateNational Cancer InstituteOncogenesPatient CarePharmacy facilityRecruitment ActivityRegulationResearchResource SharingResourcesScientistSignal TransductionSouth CarolinaTherapeuticTherapeutic Clinical TrialTimeTranslational ResearchUniversitiesbasebench to bedsidecancer preventioncellular imagingcollegeinterdisciplinary collaborationmolecular imagingmortalitynovel strategiespopulation basedpreventprogramsranpirnaseresearch and developmentresearch facility
项目摘要
DESCRIPTION (provided by applicant): The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks National Cancer Institute (NCI) designation via the P30 Cancer Center Support Grant mechanism to support its mission to reduce the cancer burden in South Carolina and beyond. As South Carolina's leading academic medical center, MUSC has been charged and supported over the past decade to build clinical, basic, translational and population-based research programs that address the state's significant cancer morbidity and mortality. Through the support of an NCI P20 Planning Grant (2001-2007), the HCC has recruited and organized 97 cancer scientists, representing six MUSC Colleges - Medicine, Pharmacy, Dental Medicine, Nursing, Health Professions and Graduate Studies - into productive and collaborative cancer research programs. These programs are: Lipid Signaling in Cancer, Cancer Genes & Molecular Regulation, Developmental Cancer Therapeutics and Cancer Immunology. A Cancer Prevention & Control program is in development. The HCC has expanded and continues to expand its research facilities and resources to enhance further growth. In 2006, the HCC completed a seven story tower adjacent to its original 85,761 ft[2] building adding more than 116,000 ft2 in research, clinical and administrative space, and MUSC has committed an additional 62,000 ft2 of research space to the HCC in two new buildings starting construction in summer 2008. As part of this P30 application, five shared research resources will be presented: Lipidomics, Flow Cytometry & Cell Sorting, Cell & Molecular Imaging, Biostatistics and Clinical Trials. The HCC has invested $1.6 million since 2004 into enhancing these five essential and critical resources. Given the rapid and ongoing development of research in the programs, the HCC has also invested another $6 million in initiating the development and optimizing the function of seven other shared resources that will greatly impact on HCC's current and future programmatic-based research initiatives. These investments have resulted in a doubling of the HCC's extramural research funding base since 2003, currently $31.2 million with NCI funding representing $12.1million. Accrual to therapeutic clinical trials has quadrupled in the same time period. This application demonstrates that HCC scientists have made significant contributions to the understanding of cancer biology and the development of novel approaches to prevent, diagnose and treat cancer.
描述(由申请人提供):南卡罗来纳州医科大学(MUSC)的霍林斯癌症中心(HCC)通过P30癌症中心支持补助金机制寻求国家癌症研究所(NCI)的指定,以支持其减少南卡罗来纳州及其他地区癌症负担的使命。作为南卡罗来纳州领先的学术医疗中心,MUSC在过去十年中一直致力于建立临床,基础,转化和基于人口的研究计划,以解决该州显著的癌症发病率和死亡率。通过NCI P20规划补助金(2001-2007年)的支持,HCC招募并组织了97名癌症科学家,代表六所MUSC学院-医学,药学,牙科医学,护理,健康护理和研究生课程-进入生产和合作癌症研究计划。这些项目包括:癌症中的脂质信号,癌症基因和分子调控,发育癌症治疗和癌症免疫学。一项癌症预防和控制计划正在制定中。HCC已经扩大并将继续扩大其研究设施和资源,以促进进一步增长。2006年,HCC在其原有的85,761英尺[2]建筑附近完成了一座七层楼高的塔楼,增加了超过116,000平方英尺的研究,临床和行政空间,MUSC已承诺在2008年夏天开始建设的两座新建筑中为HCC提供额外的62,000平方英尺的研究空间。作为P30应用程序的一部分,将提供五个共享的研究资源:脂质组学,流式细胞术和细胞分选,细胞和分子成像,生物统计学和临床试验。自2004年以来,总部合同委员会已投资160万美元,用于加强这五项基本和关键资源。鉴于这些项目研究的快速和持续发展,HCC还投资了另外600万美元,用于启动开发和优化其他七个共享资源的功能,这将极大地影响HCC当前和未来基于项目的研究计划。自2003年以来,这些投资使HCC的校外研究资金基础翻了一番,目前为3120万美元,NCI资金为1210万美元。在同一时期,治疗性临床试验的累积量翻了两番。这一应用表明,HCC科学家为理解癌症生物学和开发预防、诊断和治疗癌症的新方法做出了重大贡献。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew S Kraft其他文献
Andrew S Kraft的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew S Kraft', 18)}}的其他基金
Regulation of RNA Decapping and Degradation: A novel approach to prostate cancer therapy
RNA 脱帽和降解的调控:前列腺癌治疗的新方法
- 批准号:
10758110 - 财政年份:2023
- 资助金额:
$ 5.76万 - 项目类别:
Pim 1 Protein Kinase in Regulating Stromal Cell Biology in Prostate Cancer
Pim 1 蛋白激酶调节前列腺癌基质细胞生物学
- 批准号:
8855025 - 财政年份:2015
- 资助金额:
$ 5.76万 - 项目类别:
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan
MUSC/HCC Paul Calabresi 临床肿瘤学培训计划计划
- 批准号:
8486908 - 财政年份:2013
- 资助金额:
$ 5.76万 - 项目类别:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
靶向 Pim 1 蛋白激酶以克服对 AKT 抑制剂的耐药性
- 批准号:
8577635 - 财政年份:2013
- 资助金额:
$ 5.76万 - 项目类别:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
靶向 Pim 1 蛋白激酶以克服对 AKT 抑制剂的耐药性
- 批准号:
9039263 - 财政年份:2013
- 资助金额:
$ 5.76万 - 项目类别:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
靶向 Pim 1 蛋白激酶以克服对 AKT 抑制剂的耐药性
- 批准号:
8735893 - 财政年份:2013
- 资助金额:
$ 5.76万 - 项目类别:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
靶向 Pim 1 蛋白激酶以克服对 AKT 抑制剂的耐药性
- 批准号:
9320825 - 财政年份:2013
- 资助金额:
$ 5.76万 - 项目类别:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
靶向 Pim 1 蛋白激酶以克服对 AKT 抑制剂的耐药性
- 批准号:
8891388 - 财政年份:2013
- 资助金额:
$ 5.76万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 5.76万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 5.76万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 5.76万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 5.76万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 5.76万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 5.76万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 5.76万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 5.76万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 5.76万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 5.76万 - 项目类别:
Research Grant














{{item.name}}会员




